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Perinatal HIV-1 transmission: Fc gamma 
receptor variability associates with maternal 
infectiousness and infant susceptibility
Ria Lassaunière1,2, Alfred Musekiwa3, Glenda E. Gray4, Louise Kuhn5,6 and Caroline T. Tiemessen1,2*
Abstract 
Background: Accumulating data suggest that immune effector functions mediated through the Fc portion of 
HIV-1-specific immunoglobulin G (IgG) are a key component of HIV-1 protective immunity, affecting both disease pro-
gression and HIV-1 acquisition. Through studying Fc gamma receptor (FcγR) variants known to alter IgG Fc-mediated 
immune responses, we indirectly assessed the role of FcγR-mediated effector functions in modulating perinatal HIV-1 
transmission risk. In this study, genotypic data from 79 HIV-1 infected mothers and 78 HIV-1 infected infants (transmit-
ting cases) were compared to 234 HIV-1 infected mothers and 235 HIV-1 exposed-uninfected infants (non-transmit-
ting controls). Associations, unadjusted and adjusted for multiple comparisons, were assessed for overall transmission 
and according to mode of transmission—intrapartum (n = 31), in utero (n = 20), in utero-enriched (n = 48).
Results: The maternal FcγRIIIa-158V allele that confers enhanced antibody binding affinity and antibody-dependent 
cellular cytotoxicity capacity significantly associated with reduced HIV-1 transmission [odds ratio (OR) 0.47, 95 % 
confidence interval (CI) 0.28–0.79, P = 0.004; PBonf > 0.05]. In particular, the FcγRIIIa-158V allele was underrepresented 
in the in utero transmitting group (P = 0.048; PBonf > 0.05) and in utero-enriched transmitting groups (P = 0.0001; 
PBonf < 0.01). In both mother and infant, possession of an FcγRIIIb-HNA1b allotype that reduces neutrophil-mediated 
effector functions associated with increased transmission (OR 1.87, 95 % CI 1.08–3.21, P = 0.025; PBonf > 0.05) and 
acquisition (OR 1.91, 95 % CI 1.11–3.30, P = 0.020; PBonf > 0.05), respectively. Conversely, the infant FcγRIIIb-HNA1a|1a 
genotype was significantly protective of perinatal HIV-1 acquisition (OR 0.42, 95 % CI 0.18–0.96, P = 0.040; PBonf > 0.05).
Conclusions: The findings of this study suggest a potential role for FcγR-mediated effector functions in perinatal 
HIV-1 transmission. However, future studies are required to validate the findings of this study, in particular associations 
that did not retain significance after adjustment for multiple comparisons.
Keywords: HIV-1, Vertical infectious disease transmission, Risk factors, IgG receptors, Alleles, Antibody-dependent cell 
cytotoxicity, Phagocytosis
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Background
Beyond neutralization, immunoglobulin G (IgG) has 
the capacity to recruit potent effector functions of the 
innate immune system through engagement with Fc 
gamma receptors (FcγRs), which are widely expressed 
throughout the haematopoietic system. Directly or indi-
rectly, FcγRs mediate antiviral processes that include 
antibody-dependent cellular cytotoxicity (ADCC), 
antibody-dependent cellular phagocytosis (ADCP), res-
piratory burst, antigen display, antibody production, cell 
activation, and release of inflammatory mediators [1].
FcγR-mediated effector functions are increasingly rec-
ognized as a component of HIV-1 protective immunity 
[2]. However, the role of these effector functions in mod-
ulating perinatal HIV-1 transmission risk is currently 
undefined. Given the contribution of FcγR-mediated 
effector functions to eliminating cell-free and cell-associ-
ated virus, these processes may modify the infectiousness 
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of an HIV-1 infected mother. In addition, transplacental 
transferred anti-HIV-1 IgG may recruit innate immune 
effector functions in the foetus/infant through engaging 
FcγRs expressed on foetal/infant immune cells, and in 
this manner modify the infant’s susceptibility to HIV-1 
acquisition.
In vivo, FcγR-mediated effector functions are governed 
by a balance between activating and inhibitory FcγRs [3]. 
This balance is perturbed by functionally significant gen-
otypic variants that modulate cellular activation and ulti-
mately effector function capability. These include gene 
duplication/deletion that affects FcγR surface density [4, 
5] and amino acid changes that alter the receptor’s bind-
ing affinity for antibody subclasses (FcγRIIa-H131R and 
FcγRIIIa-F158V) [6, 7], subcellular localization (FcγRIIb-
I232T) [8], glycosylation patterns (FcγRIIIb-HNA1a|b|c) 
[9, 10], and the expression of a functional molecule 
(FcγRIIc-X57Q and c.798+1A>G) [11, 12].
Using these variants as a proxy for functional capability, 
this study indirectly assessed the potential role of FcγR-
mediated effector functions in mother-to-child trans-
mission of HIV-1. Due to the exploratory nature of the 
study, associations are reported unadjusted for multiple 
comparisons. However, adjusted associations were also 
considered. Our findings highlight a potential role for the 
FcγRIIIa-F158V variant in modulating maternal infec-
tiousness, while in both mother and infant the FcγRIIIb-
HNA1a|b|c variant associated with HIV-1 transmission.
Results
Cohort
A nested case–control study was undertaken to inves-
tigate FCGR variability in HIV-1 infected mothers and 
their infants recruited as part of four perinatal cohorts at 
two hospitals in Johannesburg, South Africa [13]. Over-
all, the four cohorts comprised 849 HIV-1 infected moth-
ers and their infants, of whom 83 (10 %) acquired HIV-1 
perinatally. In the present study, FCGR genotypic data 
from 79 HIV-1 infected mothers and 78 HIV-1 infected 
infants (transmitting cases) were compared with 234 
HIV-1 infected mothers and 235 uninfected infants (non-
transmitting controls). Mode of transmission was defined 
according to the presence/absence of detectable HIV-1 
DNA in the infant at birth and 6  weeks of age. Infants 
that tested HIV-1 positive at 6 weeks of age, but who were 
negative at birth, were considered to be infected intra-
partum (during labour and delivery), while infants that 
tested HIV-1 positive at birth were considered infected 
in utero. Infants that were HIV-1 positive at 6 weeks, but 
had no birth sample, were categorized as ‘undetermined’. 
Since 25/28 (89.2 %) mothers in the ‘undetermined’ cat-
egory received drug interventions known to reduce intra-
partum transmission [14–16], it was concluded that the 
majority of infants in this group were likely infected in 
utero and was thus combined with the in utero group to 
form an in utero-enriched group.
Transmitting mothers had significantly higher HIV-1 
plasma viral loads and lower CD4+ T cell counts com-
pared to non-transmitting mothers (Table 1). In addition, 
infants infected in utero had a significantly lower mean 
birth weight compared to exposed-uninfected infants. 
Maternal age, parity, mode of delivery, gestation, child 
sex, and reported breast feeding did not differ signifi-
cantly between transmitting mothers (total, intrapartum 
or in utero) and non-transmitting mothers.
Variants not detected in the study cohort
The FcγRIIb 2B.4 promoter haplotype (c.-386C/c.-120A) 
and expression of functional FcγRIIc are rare to absent 
in Black South African individuals [17]. Accordingly, 
in the present cohort of Black South African mothers 
and infants, none possessed the FcγRIIb 2B.4 promoter 
haplotype. Furthermore, despite 84/313 (25.3  %) moth-
ers and 81/313 (25.9 %) infants bearing an FcγRIIc-Q57 
allele, only one non-transmitting mother expressed func-
tional FcγRIIc as predicted by the FCGR2C c.798+1A>G 
splice-site variant [12].
FCGR copy number variability
The frequency of FCGR3A gene copy number variabil-
ity (CNV) was low, occurring in 17/313 (5.4 %) mothers 
and 14/313 (4.5  %) infants (Fig.  1), and did not associ-
ate with perinatal HIV-1 transmission (P  >  0.05 for all 
comparisons; Additional file 1: Table S1). FCGR3B gene 
CNV was observed more frequently in 92/313 (29.4  %) 
mothers and 100/313 (31.9 %) infants (Fig. 1). The overall 
distribution of FCGR3B gene copy number was signifi-
cantly different between exposed-uninfected infants and 
intrapartum infected infants (P = 0.029), with the intra-
partum infected group having fewer FCGR3B gene dupli-
cations and no gene deletions (Additional file  1: Table 
S1). Maternal FCGR3B gene CNV did not associate with 
HIV-1 transmission (P > 0.05 for all comparisons; Addi-
tional file 1: Table S1).
FcγR variants and infectiousness of the transmitter/mother
To determine if FcγR variants were associated with the 
infectiousness of the mother, HIV-1 transmission was 
assessed according to maternal genotypes and allele car-
riage in a univariate and multivariate model (Table  2, 
3, respectively). Overall, the maternal FcγRIIIa-F158V 
variant significantly associated with HIV-1 transmission 
(P = 0.017), while a trend was observed for the FcγRIIIb-
HNA1a|b|c variant (P = 0.058). 
Carriage of at least one maternal FcγRIIIa-158V allele 
(confers enhanced antibody binding affinity) associated 
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with a reduced odds of perinatal HIV-1 transmission 
(OR 0.47, 95  % CI 0.28–0.79, P  =  0.004). When ana-
lysed according to mode of transmission, a similar asso-
ciation was observed for the in utero transmitting group 
(OR 0.39, 95  % CI 0.16–0.99, P =  0.048) and in utero-
enriched transmitting group (OR 0.29, 95 % CI 0.15–0.55, 
P  =  0.0001), but not for the intrapartum transmitting 
group (OR 1.01, 95  % CI 0.45–2.25, P =  0.980). These 
associations remained significant for the total transmit-
ting group and in utero-enriched group in the multivari-
ate analysis (P = 0.008 and P = 0.001, respectively) and 
for the in utero-enriched group after adjustment for mul-
tiple comparisons (univariate: PBonf = 0.004; multivariate: 
PBonf = 0.042).
Possession of an FcγRIIIb-HNA1b allele (modulates 
neutrophil function) significantly associated with an 
increased odds of HIV-1 transmission in both the univar-
iate analysis (OR 1.87, 95 % CI 1.08–3.21, P = 0.025) and 
multivariate analysis (P =  0.014). A similar association 
was observed for the FcγRIIIb-HNA1b|1c genotype in 
the in utero transmitting group (OR 5.45, 95 % CI 1.21–
24.66, P  =  0.028) and in utero-enriched transmitting 
group (OR 2.45, 95 % CI 1.01–5.96, P = 0.047). However, 
these associations were not significant in the multivariate 
analysis.
The FcγRIIa-H131R and FcγRIIb-I232T variants did 
not associate with perinatal HIV-1 transmission in the 
univariate analysis. However, after adjustment for con-
founding variables, the FcγRIIa-131RR genotype (recep-
tor has reduced affinity for IgG2) and FcγRIIb-232TT 
genotype (confers reduced inhibitory capacity) associated 
with increased odds of HIV-1 transmission (Table 3).
FcγR variants and susceptibility of the recipient/infant
In addition to an association observed in the mother, 
the infant FcγRIIIb-HNA1a|b|c variant also associated 
with susceptibility to HIV-1 acquisition in the infant 
(P = 0.046). In particular, carriage of least one FcγRIIIb-
HNA1b allotype significantly associated with increased 
susceptibility to HIV-1 acquisition in the univariate 
Table 1 Demographic and clinical characteristics of mothers and infants
For comparisons with non-transmitting mothers: * P < 0.05; ** P < 0.01; *** P < 0.001
a Five unmatched mothers
b One unmatched mother
c Number of participants for whom data were available
d Different regimens of zidovudine (AZT) and lamivudine (3TC)












Nc Nc Nc Nc Nc
Median (IQR) 218 4.08 (3.20–4.67) 71 4.77 (3.77–5.34)*** 27 4.77 (3.77–5.26)** 18 4.89 (4.20–5.47)*** 44 4.81 (3.78–5.44)***
Maternal CD4+ T cell 
count
 Mean (std) 217 520 (275) 70 418 (222)** 27 402 (179)* 15 409 (276) 43 428 (247)*
Maternal age (years)
 Mean (std) 232 26.9 (5.1) 78 27.6 (5.2) 30 26.7 (5.0) 20 27.5 (5.5) 48 28.2 (5.2)
Parity
 Mean (std) 231 2.1 (1.0) 77 2.3 (1.2) 29 2.3 (1.2) 20 2.2 (1.2) 48 2.3 (1.2)
Mode of delivery [N (%)]
 Caesarean section 232 17 (7.3) 77 10 (13.0) 29 2 (6.9) 20 3 (15.0) 48 8 (16.7)
Gestation [N (%)]
 Preterm <37 weeks 215 27 (12.6) 70 12 (17.1) 25 7 (28.0) 19 4 (21.1) 45 5 (11.1)
Child sex [N (%)]
 Male 234 101 (43.1) 79 39 (49.4) 31 18 (58.0) 20 8 (40.0) 48 21 (43.8)
Birth weight (g)
 Mean (std) 231 2980 (453) 78 2889 (442) 30 2943 (400) 20 2784 (320)* 48 2856 (468)
Breast fed N (%)
 >3 days 233 34 (14.6) 78 10 (12.8) 30 5 (16.7) 20 2 (10.0) 48 5 (10.4)
Antiretrovirals
 Nevirapine 234 114 (48.7) 79 47 (59.5) 31 11 (35.5) 20 13 (65.0) 48 36 (75.0)**
 Triple drug therapy 234 6 (2.6) 79 2 (2.5) 31 0 20 0 48 2 (4.2)
 Other drugsd 234 11 (4.7) 79 6 (7.6) 31 3 (9.7) 20 1 (5.0) 48 3 (6.3)
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analysis (OR 1.91, 95 % CI 1.11–3.30, P = 0.020; Table 4) 
and multivariate analysis (P  =  0.019; Table  5). Con-
versely, homozygosity for the FcγRIIIb-HNA1a allotype 
associated with reduced odds of HIV-1 acquisition in 
the total infected group (OR 0.42, 95  % CI 0.18–0.96, 
P  =  0.040) and intrapartum infected group (OR 0.19, 
95  % CI 0.04–0.89, P =  0.035). The protective effect of 
FcγRIIIb-HNA1a homozygosity was also observed when 
compared to other allotype combinations, however not 
all comparisons remained significant in the multivariate 
analysis (Additional file 2: Table S2). 
Linkage disequilibrium at the low affinity FCGR gene locus
Linkage disequilibrium (LD) between the different 
FcγR variants could potentially modulate associations 
observed for the individual FcγRs. Given the strong asso-
ciation of the maternal FcγRIIIa-F158V variant with peri-
natal HIV-1 transmission, we determined LD in the study 
cohort (Fig.  2) and adjusted for its possible confound-
ing effect on the associations observed for FcγRIIIb-
HNA1a|b|c, FcγRIIa-H131R and FcγRIIb-I232T in the 
multivariate analysis (Table 6).
To determine LD for the FcγRIIIb-HNA1a|b|c allo-
types, we used, as a tag-variant, one of four amino acid 
changes that differentiate HNA1a from HNA1b and 
HNA1c (p.Na65Sbc, rs448740) as well as the variant 
that differentiates HNA1c from HNA1a and HNA1b 
(p.Aab78Dc, rs5030738). The maternal FcγRIIIb-Na65Sbc 
variant was not in LD with FcγRIIIa-F158V (P =  0.057, 
D′  =  0.189, r2  =  0.020), while the p.Aab78Dc variant 
was in moderate LD with FcγRIIIa-F158V (P  =  0.024, 
D′  =  0.471, r2  =  0.029) with the FcγRIIIa-158V allele 
overrepresented in individuals bearing an FcγRIIIb-
78A allele (HNA1c individuals) compared to FcγRIIIb-
78DD individuals (59 vs. 20  %). Following adjustment 
for FcγRIIIa-F158V in the multivariate analysis, the asso-
ciations previously observed for the FcγRIIIb-HNA1b 
allotype strengthened for both the total and in utero-
enriched transmitting groups (Table  6). Similarly, sig-
nificance was retained in the infants with associations 
strengthening for the FcγRIIIb-HNA1a+|1b+|1c+ geno-
type in the in utero-enriched infected group and carriage 
of an HNA1b allotype in the total infected and in utero-
enriched infected groups (Table 6). Overall, this suggests 
that the observed associations between the FcγRIIIb-
HNA1a|b|c variant and perinatal HIV-1 transmission are 
not only independent of FcγRIIIa-F158V, but also poten-
tially negatively confounded by FcγRIIIa-F158V.
Both maternal FcγRIIa-H131R and FcγRIIb-I232T 
was in moderate LD with FcγRIIIa-F158V (P  <  0.0001, 
Fig. 1 The distribution of FCGR3A and FCGR3B gene copy number in HIV-1 infected mothers (a, b, respectively) and their infants (c, d, respectively)
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Table 2 FcγR genotypes and allele carriage in HIV-1 non-transmitting and transmitting mothers
Non-transmitting Total transmitting Intrapartum transmitting
N (%) N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIa (rs1801274) Overall association P = 0.379 ns P = 0.688 ns
Genotype
 131HH (ref ) 60 (25.6) 15 (19.0) 1 6 (19.4) 1
 131HR 106 (45.3) 36 (45.6) 1.36 (0.69–2.68) P = 0.378 ns 14 (45.2) 1.32 (0.48–3.62) P = 0.558 ns
 131RR 68 (29.1) 28 (35.4) 1.65 (0.80–3.37) P = 0.172 ns 11 (35.5) 1.62 (0.56–4.64) P = 0.371 ns
Allele carriage
 ≥1 131H allele 166 (70.9) 51 (64.6) 0.75 (0.43–1.28) P = 0.288 ns 20 (64.5) 0.74 (0.34–1.64) P = 0.464 ns
 ≥1 131R allele 174 (74.4) 64 (81.0) 1.47 (0.78–2.77) P = 0.233 ns 25 (80.6) 1.44 (0.56–3.67) P = 0.449 ns
FcγRIIb (rs1050501) Overall association P = 0.194 ns P = 0.397 ns
Genotype
 232II (ref ) 113 (48.3) 32 (40.5) 1 12 (38.7) 1
 232IT 103 (44.0) 36 (45.6) 1.23 (0.71–2.13) P = 0.450 ns 15 (48.4) 1.37 (0.61–3.07) P = 0.442 ns
 232TT 18 (7.7) 11 (13.9) 2.16 (0.93–5.03) P = 0.075 ns 4 (12.9) 2.09 (0.61–7.20) P = 0.242 ns
Allele carriage
 ≥1 232I allele 216 (92.3) 68 (86.3) 0.52 (0.23–1.14) P = 0.103 ns 27 (87.1) 0.56 (0.18–1.79) P = 0.239 ns
 ≥1 232T allele 121 (51.7) 47 (59.5) 1.37 (0.82–2.30) P = 0.231 ns 19 (61.3) 1.48 (0.69–3.18) P = 0.317 ns
FcγRIIIa (rs396991) Overall association P = 0.017 ns P = 0.380 ns
Genotype
 158F/FF/FF (ref ) 76 (32.5) 40 (50.6) 1 10 (32.3) 1
 158FV/FFV/FVV 121 (51.7) 31 (39.2) 0.49 (0.28–0.84) P = 0.010 ns 19 (61.3) 1.19 (0.53–2.70) P = 0.672 ns
 158V/VV 36 (15.4) 8 (10.1) 0.41 (0.17–0.97) P = 0.041 ns 2 (6.5) 0.41 (0.09–1.97) P = 0.266 ns
Allele carriage
 ≥1 158F allele 197 (84.2) 71 (89.9) 1.67 (0.74–3.75) P = 0.217 ns 29 (93.5) 2.72 (0.62–11.91) P = 0.183 ns
 ≥1 158V allele 157 (67.1) 39 (49.4) 0.47(0.28–0.79) P = 0.004 ns 21 (67.7) 1.01 (0.45–2.25) P = 0.980 ns
FcγRIIIb Overall association P = 0.058 ns P = 0.647 ns
Genotype
 HNA1a+/1b−/1c− 51 (21.8) 13 (16.5) 0.68 (0.32–1.44) P = 0.315 ns 4 (12.9) 0.51 (0.15–1.70) P = 0.276 ns
 HNA1a−/1b+/1c− 23 (9.8) 7 (8.9) 0.81 (0.31–2.11) P = 0.668 ns 4 (12.9) 1.14 (0.33–3.92) P = 0.837 ns
 HNA1a−/1b−/1c+ 13 (5.6) 0 (0) – 0 (0) –
 HNA1a+/1b+/1c− (ref ) 72 (30.8) 27 (34.2) 1 11 (35.5) 1
 HNA1a+/1b−/1c+ 40 (17.1) 11 (13.9) 0.73 (0.33–1.63) P = 0.448 ns 5 (16.1) 0.82 (0.27–2.52) P = 0.727 ns
 HNA1a−/1b+/1c+ 22 (9.4) 17 (21.5) 2.06 (0.95–4.46) P = 0.066 ns 5 (16.1) 1.49 (0.47–4.75) P = 0.502 ns
 HNA1a+/1b+/1c+ 12 (5.1) 4 (5.1) 0.89 (0.26–3.00) P = 0.849 ns 2 (6.5) 1.09 (0.21–5.54) P = 0.916 ns
Allele carriage
 ≥1 HNA1a allotype 175 (74.8) 55 (69.6) 0.77 (0.44–1.36) P = 0.369 ns 22 (71.0) 0.82 (0.36–1.89) P = 0.648 ns
 ≥1 HNA1b allotype 129 (55.1) 55 (69.6) 1.87 (1.08–3.21) P = 0.025 ns 22 (71.0) 1.99 (0.88–4.50) P = 0.099 ns
 ≥1 HNA1c allotype 87 (37.2) 32 (40.5) 1.15 (0.68–1.94) P = 0.599 ns 12 (38.7) 1.07 (0.49–2.30) P = 0.869 ns
In utero transmitting In utero-enriched transmitting
N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIa (rs1801274) P = 0.182 ns P = 0.545 ns
Genotype
 131HH (ref ) 2 (10.0) 1 9 (18.8) 1
 131HR 9 (45.0) 2.55 (0.53–12.17) P = 0.241 ns 22 (45.8) 1.38 (0.60–3.20) P = 0.447 ns
 131RR 9 (45.0) 3.97 (0.83–19.10) P = 0.085 ns 17 (35.4) 1.67 (0.69–4.02) P = 0.225 ns
Allele carriage
 ≥1 131H allele 11 (55.0) 0.50 (0.20–1.26) P = 0.143 ns 31 (64.6) 0.75 (0.39–1.44) P = 0.383 ns
 ≥1 131R allele 18 (90.0) 3.10 (0.70–13.77) P = 0.136 ns 39 (81.3) 1.49 (0.68–3.27) P = 0.314 ns
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D′  =  0.351, r2  =  0.077 and P  =  0.002, D′  =  0.448, 
r2  =  0.052, respectively), with the FcγRIIIa-158V allele 
overrepresented in individuals bearing an FcγRIIa-131H 
allele compared to FcγRIIa-131RR individuals (66 vs. 
39  %) and in individuals bearing an FcγRIIb-232I allele 
compared to FcγRIIb-232TT individuals (59 vs. 39  %). 
When adjusted for FcγRIIIa-F158V in the multivari-
ate analysis, all associations for the FcγRIIa-H131R and 
FcγRIIb-I232T weakened with the majority losing sig-
nificance (Table  6). This suggests that the associations 
observed for FcγRIIa-H131R and FcγRIIb-I232T poten-
tially resulted from LD with FcγRIIIa-F158V.
Discussion
The extent to which FcγR-mediated effector mecha-
nisms contribute to the risk of HIV-1 transmission and 
acquisition is currently undefined. Through the study of 
FcγR functional variants we indirectly demonstrated a 
role for FcγR-mediated effector functions in modulating 
perinatal HIV-1 transmission and acquisition. Our find-
ings indicate that the FcγRIIIa-F158V variant that alters 
antibody binding affinity and functional capacity is asso-
ciated with infectiousness of an HIV-1 infected mother, 
while the FcγRIIIb-HNA1a|b|c variant that affects neu-
trophil effector function is associated with both maternal 
infectiousness and infant susceptibility.
Table 2 continued
In utero transmitting In utero-enriched transmitting
N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIb (rs1050501) P = 0.125 ns P = 0.274 ns
Genotype
 232II (ref ) 10 (50.0) 1 20 (41.7) 1
 232IT 6 (30.0) 0.66 (0.23–1.87) P = 0.434 ns 21 (43.8) 1.15 (0.59–2.25) P = 0.678 ns
 232TT 4 (20.0) 2.51 (0.71–8.87) P = 0.153 ns 7 (14.6) 2.20 (0.81–5.94) P = 0.121 ns
Allele carriage
 ≥1 232I allele 16 (80.0) 0.33 (0.10–1.10) P = 0.072 ns 41 (85.4) 0.49 (0.19–1.24) P = 0.133 ns
 ≥1 232T allele 10 (50.0) 0.93 (0.37–2.33) P = 0.883 ns 28 (58.3) 1.31 (0.70–2.45) P = 0.403 ns
FcγRIIIa (rs396991) P = 0.137 ns P = 0.0004 0.017
Genotype
 158F/FF/FF (ref ) 11 (55.0) 1 30 (62.5) 1
 158FV/FFV/FVV 8 (40.0) 0.46 (0.18–1.19) P = 0.108 ns 12 (25.0) 0.25 (0.12–0.52) P = 0.0001 0.004
 158V/VV 1 (5.0) 0.19 (0.02–1.50) P = 0.115 ns 6 (12.5) 0.41 (0.16–1.07) P = 0.069 ns
Allele carriage
 ≥1 158F allele 19 (95.0) 3.57 (0.46–27.48) P = 0.222 ns 42 (87.5) 1.31 (0.52–3.31) P = 0.562 ns
 ≥1 158V allele 9 (45.0) 0.39 (0.16–0.99) P = 0.048 ns 18 (37.5) 0.29 (0.15–0.55) P = 0.0001 0.004
FcγRIIIb P = 0.320 ns P = 0.123 ns
Genotype
 HNA1a+/1b−/1c− 6 (30.0) 2.82 (0.67–11.82) P = 0.155 ns 9 (18.8) 0.79 (0.33–1.94) P = 0.612 ns
 HNA1a−/1b+/1c− 1 (5.0) 1.04 (0.10–10.53) P = 0.971 ns 3 (6.3) 0.59 (0.16–2.20) P = 0.429 ns
 HNA1a−/1b−/1c+ 0 (0) – 0 (0) –
 HNA1a+/1b+/1c− 
(ref )
3 (15.0) 1 16 (33.3) 1
 HNA1a+/1b−/1c+ 4 (20.0) 2.40 (0.51–11.26) P = 0.267 ns 6 (12.5) 0.68 (0.24–1.86) P = 0.448 ns
 HNA1a−/1b+/1c+ 5 (25.0) 5.45 (1.21–24.66) P = 0.028 ns 12 (25.0) 2.45 (1.01–5.96) P = 0.047 ns
 HNA1a+/1b+/1c+ 1 (5.0) 2.00 (0.19–20.85) P = 0.562 ns 2 (4.2) 0.75 (0.15–3.68) P = 0.723 ns
Allele carriage
 ≥1 HNA1a allotype 14 (70.0) 0.79 (0.29–2.14) P = 0.638 ns 33 (68.8) 0.74 (0.38–1.46) P = 0.388 ns
 ≥1 HNA1b allotype 10 (50.0) 0.81 (0.33–2.03) P = 0.659 ns 33 (68.8) 1.79 (0.92–3.47) P = 0.085 ns
 ≥1 HNA1c allotype 10 (50.0) 1.69 (0.68–4.22) P = 0.262 ns 20 (41.7) 1.21 (0.64–2.27) P = 0.560 ns
P values less than 0.05 are indicated in italics
PBonf Bonferroni corrected P value, OR odds ratio, CI confidence interval, ns not statistically significant, –, the variable of interest was not detected in any of the cases 
and thus could not be analysed
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Table 3 Maternal FcγR variants associated with perinatal HIV-1 transmission after adjusting for confounding variables
Total transmitting Intrapartum transmitting
Univariate Adjusted for VLa PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
FcγRIIa (rs1801274)
Genotype
 131HH (ref ) 1 1
 131HR P = 0.378 1.81 (0.82–3.99) P = 0.141 ns P = 0.558 1.43 (0.46–4.46) P = 0.539 ns
 131RR P = 0.172 2.59 (1.14–5.87) P = 0.023 ns P = 0.371 2.57 (0.80–8.26) P = 0.113 ns
Allele carriage
 ≥1 131H allele P = 0.288 0.58 (0.33–1.05) P = 0.071 ns P = 0.464 0.49 (0.21–1.16) P = 0.106 ns
 ≥1 131R allele P = 0.233 2.11 (1.00–4.42) P = 0.049 ns P = 0.449 1.82 (0.64–5.23) P = 0.263 ns
FcγRIIb (rs1050501)
Genotype
 232II (ref ) 1 1
 232IT P = 0.450 1.29 (0.71–2.35) P = 0.408 ns P = 0.442 1.60 (0.65–3.93) P = 0.309 ns
 232TT P = 0.075 2.80 (1.11–7.10) P = 0.030 ns P = 0.242 3.25 (0.87–12.17) P = 0.080 ns
Allele carriage
 ≥1 232I allele P = 0.103 0.41 (0.17–0.97) P = 0.043 ns P = 0.239 0.40 (0.12–1.33) P = 0.133 ns
 ≥1 232T allele P = 0.231 1.49 (0.84–2.62) P = 0.171 ns P = 0.317 1.81 (0.77–4.28) P = 0.175 ns
FcγRIIIa (rs396991)
Genotype
 158F/FF/FF (ref ) 1 1
 158FV/FFV/FVV P = 0.010 0.51 (0.28–0.92) P = 0.026 ns P = 0.672 1.09 (0.45–2.64) P = 0.850 ns
 158V/VV P = 0.041 0.30 (0.11–082) P = 0.018 ns P = 0.266 0.20 (0.02–1.70) P = 0.141 ns
Allele carriage
 ≥1 158F allele P = 0.217 2.29 (0.89–5.88) P = 0.084 ns P = 0.183 5.22 (0.67–40.41) P = 0.114 ns
 ≥1 158V allele P = 0.004 0.46 (0.26–0.82) P = 0.008 ns P = 0.980 0.89 (0.37–2.12) P = 0.786 ns
FcγRIIIb
Genotype
 HNA1a+/1b−/1c− P = 0.315 0.47 (0.20–1.10) P = 0.083 ns P = 0.276 0.45 (0.12–1.61) P = 0.218 ns
 HNA1a−/1b+/1c− P = 0.668 0.90 (0.33–2.46) P = 0.839 ns P = 0.837 1.31 (0.35–4.87) P = 0.683 ns
 HNA1a−/1b−/1c+ – – – –
 HNA1a+/1b+/1c− (ref ) 1 1
 HNA1a+/1b−/1c+ P = 0.448 0.63 (0.26–1.51) P = 0.300 ns P = 0.727 0.68 (0.19–2.42) P = 0.547 ns
 HNA1a−/1b+/1c+ P = 0.066 1.37 (0.59–3.19) P = 0.466 ns P = 0.502 1.20 (0.35–4.15) P = 0.777 ns
 HNA1a+/1b+/1c+ P = 0.849 0.42 (0.10–1.71) P = 0.226 ns P = 0.916 0.42 (0.05–3.72) P = 0.433 ns
Allele carriage
 ≥1 HNA1a allotype P = 0.369 0.78 (0.43–1.44) P = 0.433 ns P = 0.648 0.73 (0.30–1.75) P = 0.481 ns
 ≥1 HNA1b allotype P = 0.025 2.11 (1.16–3.85) P = 0.014 ns P = 0.099 2.18 (0.90–5.33) P = 0.086 ns
 ≥1 HNA1c allotype P = 0.599 0.95 (0.54–1.68) P = 0.865 ns P = 0.869 0.88 (0.38–2.04) P = 0.759 ns
In utero transmitting In utero-enriched transmitting
Univariate Adjusted for VL + bwt PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
FcγRIIa (rs1801274)
Genotype
 131HH (ref ) 1 1
 131HR P = 0.241 5.74 (0.66–49.93) P = 0.113 ns P = 0.447 2.28 (0.84–6.17) P = 0.105 ns
 131RR P = 0.085 11.46 (1.29–101.86) P = 0.029 ns P = 0.225 2.82 (1.01–7.89) P = 0.048 ns
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The significance of FcγR-mediated effector functions 
in maintaining immune homeostasis is validated by the 
association of functionally significant FcγR variants with 
immune disorders [18]. Here we describe an association 
between the high binding FcγRIIIa allele and reduced 
maternal infectiousness in perinatal transmission of 
HIV-1. In particular, carriage of the FcγRIIIa-158V allele 
by the mother was associated with ~50  % reduction in 
the odds of HIV-1 transmission. The significant asso-
ciation in the in utero-enriched transmission group, but 
not in the intrapartum group, suggests that the underly-
ing mechanism may be more pronounced at the mater-
nofoetal interface. FcγRIIIa-bearing leukocytes, including 
natural killer cells, macrophages and γδ T lymphocytes, 
are readily recruited to the decidua where they likely 
contribute to eliminating cell-associated HIV-1 through 
Table 3 continued
In utero transmitting In utero-enriched transmitting
Univariate Adjusted for VL + bwt PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
Allele carriage
 ≥1 131H allele P = 0.143 0.34 (0.12–0.97) P = 0.045 ns P = 0.383 0.63 (0.32–1.27) P = 0.200 ns
 ≥1 131R allele P = 0.136 7.65 (0.94–62.32) P = 0.057 ns P = 0.314 2.50 (0.97–6.40) P = 0.057 ns
FcγRIIb (rs1050501)
Genotype
 232II (ref ) 1
 232IT P = 0.434 0.67 (0.22–2.06) P = 0.487 ns P = 0.678 1.15 (0.56–2.35) P = 0.707 ns
 232TT P = 0.153 3.38 (0.73–15.61) P = 0.119 ns P = 0.121 2.57 (0.85–7.74) P = 0.094 ns
Allele carriage
 ≥1 232I allele P = 0.072 0.25 (0.06–1.07) P = 0.062 ns P = 0.133 0.42 (0.15–1.18) P = 0.100 ns
 ≥1 232T allele P = 0.883 0.93 (0.34–2.54) P = 0.891 ns P = 0.403 1.33 (0.67–2.61) P = 0.412 ns
FcγRIIIa (rs396991)
Genotype
 158F/FF/FF (ref ) 1 1
 158FV/FFV/FVV P = 0.108 0.60 (0.21–1.71) P = 0.341 ns P = 0.0001 0.29 (0.14–0.63) P = 0.002 ns
 158V/VV P = 0.115 0.19 (0.02–1.68) P = 0.135 ns P = 0.069 0.34 (0.11–0.98) P = 0.046 ns
Allele carriage
 ≥1 158F allele P = 0.222 4.01 (0.48–33.16) P = 0.198 ns P = 0.562 1.71 (0.61–4.80) P = 0.305 ns
 ≥1 158V allele P = 0.048 0.50 (0.18–1.36) P = 0.174 ns P = 0.0001 0.31 (0.15–0.62) P = 0.001 0.042
FcγRIIIb
Genotype
 HNA1a+/1b−/1c− P = 0.155 1.44 (0.30–6.85) P = 0.644 ns P = 0.612 0.45 (0.16–1.24) P = 0.124 ns
 HNA1a−/1b+/1c− P = 0.971 1.26 (0.12–13.63) P = 0.851 ns P = 0.429 0.66 (0.17–2.56) P = 0.544 ns




 HNA1a+/1b−/1c+ P = 0.267 1.88 (0.37–9.46) P = 0.442 ns P = 0.448 0.59 (0.20–1.68) P = 0.321 ns
 HNA1a−/1b+/1c+ P = 0.028 3.10 (0.60–15.95) P = 0.177 ns P = 0.047 1.53 (0.58–4.02) P = 0.388 ns
 HNA1a+/1b+/1c+ P = 0.562 1.10 (0.10–12.45) P = 0.939 ns P = 0.723 0.44 (0.08–2.28) P = 0.326 ns
Allele carriage
 ≥1 HNA1a allotype P = 0.638 0.85 (0.28–2.63) P = 0.783 ns P = 0.388 0.79 (0.38–1.64) P = 0.523 ns
 ≥1 HNA1b allotype P = 0.659 1.09 (0.39–3.02) P = 0.868 ns P = 0.085 2.23 (1.08–4.62) P = 0.031 ns
 ≥1 HNA1c allotype P = 0.262 1.51 (0.55–4.14) P = 0.420 ns P = 0.560 1.04 (0.53–2.06) P = 0.904 ns
a The multivariate analysis adjusted for demographic and clinical variables that independently associated with transmission. Due to high correlation with viral load, 
CD4 T cell counts were not included in the multivariate model
P values less than 0.05 are indicated in italics
PBonf Bonferroni corrected P value, AOR adjusted odds ratio, CI confidence interval, VL viral load, bwt birth weight, ns not statistically significant, –, the variable of 
interest was not detected in any of the cases and thus could not be analysed
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Table 4 FcγR genotypes and allele carriage in HIV-1 exposed-uninfected and infected infants
Exposed-uninfected Total infected Intrapartum infected
N (%) N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIa (rs1801274) Overall association P = 0.704 ns P = 0.907 ns
Genotype
 131HH (ref ) 47 (20.0) 19 (24.4) 1 7 (22.6) 1
 131HR 116 (49.4) 36 (46.2) 0.77 (0.40–1.47) P = 0.426 ns 14 (45.2) 0.81 (0.31–2.13) P = 0.670 ns
 131RR 72 (30.6) 23 (29.5) 0.79 (0.39–1.61) P = 0.516 ns 10 (32.3) 0.93 (0.33–2.62) P = 0.895 ns
Allele carriage
 ≥1 131H allele 163 (69.4) 55 (70.5) 1.06 (0.60–1.85) P = 0.848 ns 21 (67.7) 0.93 (0.42–2.07) P = 0.854 ns
 ≥1 131R allele 188 (80.0) 59 (75.6) 0.76 (0.42–1.43) P = 0.414 ns 24 (77.4) 0.86 (0.35–2.11) P = 0.737 ns
FcγRIIb (rs1050501) Overall association P = 0.278 ns P = 0.773 ns
Genotype
 232II (ref ) 116 (49.4) 33 (42.3) 1 14 (45.2) 1
 232IT 90 (38.3) 30 (38.5) 1.17 (0.67–2.06) P = 0.583 ns 12 (38.7) 1.10 (0.49–2.51) P = 0.811 ns
 232TT 29 (12.3) 15 (19.2) 1.82 (0.87–3.79) P = 0.110 ns 5 (16.1) 1.43 (0.48–4.29) P = 0.525 ns
Allele carriage
 ≥1 232I allele 206 (86.8) 63 (78.6) 0.59 (0.30–1.17) P = 0.132 ns 26 (83.9) 0.73 (0.26–2.06) P = 0.554 ns
 ≥1 232T allele 119 (47.2) 45 (55.7) 1.33 (0.79–2.23) P = 0.280 ns 17 (54.8) 1.18 (0.56–2.51) P = 0.660 ns
FcγRIIIa (rs396991) Overall association P = 0.339 ns P = 0.964 ns
Genotype
 158F/FF/FF (ref ) 86 (36.6) 34 (43.6) 1 12 (38.7) 1
 158FV/FFV/FVV 118 (50.2) 38 (48.7) 0.81 (0.47–1.40) P = 0.456 ns 15 (48.4) 0.91 (0.41–2.04) P = 0.821 ns
 158V/VV 31 (13.2) 6 (7.7) 0.49 (0.19–1.28) P = 0.145 ns 4 (12.9) 0.92 (0.28–3.08) P = 0.899 ns
Allele carriage
 ≥1 158F allele 194 (82.6) 72 (92.3) 0.75 (0.44–1.26) P = 0.272 ns 27 (87.1) 0.91 (0.42–1.97) P = 0.819 ns
 ≥1 158V allele 149 (63.4) 44 (56.4) 1.82 (0.73–4.55) P = 0.198 ns 19 (61.3) 1.03(0.34–3.13) P = 0.964 ns
FcγRIIIb Overall association P = 0.046 ns P = 0.023 ns
Genotype
 HNA1a+/1b−/1c− 58 (24.7) 9 (11.5) 0.42 (0.18–0.96) P = 0.040 ns 2 (6.5) 0.19(0.04–0.89) P = 0.035 ns
 HNA1a−/1b+/1c− 25 (10.6) 7 (9.0) 0.76 (0.29–1.95) P = 0.565 ns 1 (3.2) 0.22 (0.03–1.81) P = 0.160 ns
 HNA1a−/1b−/1c+ 14 (6.0) 4 (5.1) 0.77 (0.23–2.55) P = 0.672 ns 0 (0) –
 HNA1a+/1b+/1c− (ref ) 73 (31.2) 27 (34.6) 1 13 (41.9) 1
 HNA1a+/1b−/1c+ 36 (15.3) 11 (14.1) 0.83 (0.37–1.85) P = 0.643 ns 7 (22.6) 1.09 (0.40–2.97) P = 0.863 ns
 HNA1a−/1b+/1c+ 22 (9.4) 13 (16.7) 1.60 (0.71–3.61) P = 0.260 ns 7 (22.6) 1.79 (0.63–5.03) P = 0.272 ns
 HNA1a+/1b+/1c+ 7 (3.0) 7 (9.0) 2.70 (0.87–8.43) P = 0.086 ns 1 (3.2) 0.80 (0.09–7.07) P = 0.843 ns
Allele carriage
 ≥1 HNA1a allotype 174 (74.0) 54 (69.2) 0.79 (0.45–1.38) P = 0.408 ns 23 (74.2) 1.01 (0.43–2.37) P = 0.986 ns
 ≥1 HNA1b allotype 127 (54.0) 54 (69.2) 1.91 (1.11–3.30) P = 0.020 ns 22 (71.0) 2.08 (0.92–4.70) P = 0.079 ns
 ≥1 HNA1c allotype 79 (33.6) 35 (44.9) 1.61 (0.95–2.71) P = 0.075 ns 15 (48.4) 1.85 (0.87–3.94) P = 0.110 ns
In utero infected In utero-enriched infected
N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIa (rs1801274) P = 0.265 ns P = 0.693 ns
Genotype
 131HH (ref ) 4 (21.1) 1 12 (25.5) 1
 131HR 6 (31.6) 0.61 (0.16–2.25) P = 0.456 ns 22 (46.8) 0.74 (0.34–1.62) P = 0.455 ns
 131RR 9 (47.4) 1.47 (0.43–5.04) P = 0.541 ns 13 (27.7) 0.71 (0.30–1.68) P = 0.433 ns
Allele carriage
 ≥1 131H allele 10 (52.6) 0.49 (0.19–1.26) P = 0.139 ns 34 (72.3) 1.16 (0.58–2.32) P = 0.685 ns
 ≥1 131R allele 15 (78.9) 0.94 (0.30–2.96) P = 0.912 ns 35 (74.5) 0.73 (0.35–1.51) P = 0.396 ns
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ADCC [19, 20]. While decidual natural killer cells are 
primarily FcγRIIIa negative during a healthy pregnancy, 
they likely upregulate FcγRIIIa expression in the presence 
of HIV-1 as demonstrated for other perinatally transmit-
ted viruses—human cytomegalovirus and hepatitis C 
virus [21, 22]. Since cell-associated HIV-1 is thought to 
be more infectious in utero compared to cell-free virus 
[23], ADCC-mediated killing of HIV-1 infected cells may 
contribute to protective immunity at the maternofoetal 
interface. Of consequence, the FcγRIIIa-F158V variant 
impacts on ADCC capacity, such that the FcγRIIIa-158V 
allele exhibits enhanced IgG binding and ADCC capac-
ity compared to the FcγRIIIa-158F allele [7, 24]. The 
decreased in utero transmission risk associated with the 
FcγRIIIa-158V allele suggests that the enhanced ADCC 
capacity conferred by this variant may potentiate elimi-
nation of cell-associated HIV-1 and reduce the odds of 
HIV-1 crossing the placenta through cell–cell interac-
tions. However, the role of ADCC and other potential 
FcγRIIIa-mediated immune mechanisms—systemic or 
localized—in perinatal HIV-1 transmission needs to be 
further elucidated.
In contrast to that observed for the FcγRIIIa-F158V 
variant, an association between the FcγRIIIb-HNA1a|b|c 
allotype and perinatal HIV-1 transmission was observed 
in both the mother and infant. The different FcγRIIIb 
allotypes arise from multiple amino acid substitutions 
that do not alter antibody binding affinity, but affect the 
Table 4 continued
In utero infected In utero-enriched infected
N (%) OR (95 % CI) P value PBonf N (%) OR (95 % CI) P value PBonf
FcγRIIb (rs1050501) P = 0.083 ns P = 0.218 ns
Genotype
 232II (ref ) 7 (36.8) 1 19 (40.4) 1
 232IT 6 (31.6) 1.10 (0.36–3.40) P = 0.862 ns 18 (38.3) 1.22 (0.61–2.46) P = 0.577 ns
 232TT 6 (31.6) 3.43 (1.07–10.98) P = 0.038 ns 10 (21.3) 2.11 (0.88–5.01) P = 0.092 ns
Allele carriage
 ≥1 232I allele 13 (68.4) 0.31 (0.11–0.87) P = 0.026 ns 37 (78.7) 0.52 (0.23–1.16) P = 0.110 ns
 ≥1 232T allele 12 (63.2) 1.67 (0.64–4.39) P = 0.298 ns 28 (59.6) 1.44 (0.76–2.71) P = 0.264 ns
FcγRIIIa (rs396991) P = 0.711 ns P = 0.145 ns
Genotype
 158F/FF/FF (ref ) 9 (47.4) 1 22 (46.8) 1
 158FV/FFV/FVV 8 (42.1) 0.65 (0.24–1.75) P = 0.391 ns 23 (48.9) 0.76 (0.40–1.46) P = 0.410 ns
 158V/VV 2 (10.5) 0.62 (0.13–3.01) P = 0.550 ns 2 (4.3) 0.25 (0.06–1.14) P = 0.073 ns
Allele carriage
 ≥1 158F allele 17 (89.5) 0.64 (0.25–1.64) P = 0.354 ns 45 (95.7) 0.66 (0.35–1.23) P = 0.190 ns
 ≥1 158V allele 10 (52.6) 1.29 (0.28–5.87) P = 0.740 ns 25 (53.2) 3.42 (0.79–14.81) P = 0.100 ns
FcγRIIIb P = 0.182 ns P = 0.079 ns
Genotype
 HNA1a+/1b−/1c− 3 (15.8) 0.76 (0.17–3.29) P = 0.709 ns 7 (14.9) 0.63 (0.24–1.66) P = 0.350 ns
 HNA1a−/1b+/1c− 1 (5.3) 0.58 (0.07–5.24) P = 0.631 ns 6 (12.8) 1.25 (0.43–3.61) P = 0.678 ns
 HNA1a−/1b−/1c+ 1 (5.3) 1.04 (0.11–9.62) P = 0.970 ns 4 (8.5) 1.49 (0.43–5.20) P = 0.532 ns
 HNA1a+/1b+/1c− 
(ref )
5 (26.3) 1 14 (29.8) 1
 HNA1a+/1b−/1c+ 2 (10.5) 0.81 (0.15–4.39) P = 0.808 ns 4 (8.5) 0.58 (0.18–1.89) P = 0.365 ns
 HNA1a−/1b+/1c+ 5 (26.3) 3.32 (0.88–12.52) P = 0.077 ns 6 (12.8) 1.42 (0.49–4.14) P = 0.518 ns
 HNA1a+/1b+/1c+ 2 (10.5) 4.17 (0.68–25.59) P = 0.123 ns 6 (12.8) 4.47 (1.30–15.31) P = 0.017 ns
Allele carriage
 ≥1 HNA1a allotype 12 (63.2) 0.60 (0.23–1.60) P = 0.307 ns 31 (66.0) 0.70 (0.35–1.33) P = 0.258 ns
 ≥1 HNA1b allotype 13 (68.4) 1.84 (0.68–5.01) P = 0.231 ns 32 (68.1) 1.81 (0.93–3.53) P = 0.079 ns
 ≥1 HNA1c allotype 10 (52.6) 2.19 (0.86–5.62) P = 0.101 ns 20 (42.6) 1.46 (0.77–2.77) P = 0.243 ns
P values less than 0.05 are indicated in italics
PBonf Bonferroni corrected P value, OR odds ratio, CI confidence interval, ns not statistically significant, –, the variable of interest was not detected in any of the cases 
and thus could not be analysed
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Table 5 Infant FcγR variants associated with perinatal HIV-1 acquisition after adjusting for confounding variables
Total infected Intrapartum infected
Univariate Adjusted for VLa PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
FcγRIIa (rs1801274)
Genotype
 131HH (ref ) 1 1
 131HR P = 0.426 0.79 (0.38–1.62) P = 0.519 ns P = 0.670 0.80 (0.27–2.32) P = 0.685 ns
 131RR P = 0.516 0.84 (0.39–1.83) P = 0.657 ns P = 0.895 0.97 (0.31–2.97) P = 0.951 ns
Allele carriage
 ≥1 131H allele P = 0.848 1.01 (0.55–1.85) P = 0.970 ns P = 0.854 0.89 (0.37–2.12) P = 0.792 ns
 ≥1 131R allele P = 0.414 0.81 (0.41–1.59) P = 0.536 ns P = 0.737 0.87 (0.32–2.32) P = 0.774 ns
FcγRIIb (rs1050501)
Genotype
 232II (ref ) 1 1
 232IT P = 0.583 1.29 (0.70–2.39) P = 0.415 ns P = 0.811 1.40 (0.57–3.44) P = 0.469 ns
 232TT P = 0.110 1.97 (0.89–4.37) P = 0.096 ns P = 0.525 1.82 (0.56–5.90) P = 0.317 ns
Allele carriage
 ≥1 232I allele P = 0.132 0.57 (0.28–1.20) P = 0.140 ns P = 0.554 0.65 (0.22–1.90) P = 0.429 ns
 ≥1 232T allele P = 0.280 1.46 (0.83–2.57) P = 0.195 ns P = 0.660 1.50 (0.65–3.47) P = 0.344 ns
FcγRIIIa (rs396991)
Genotype
 158F/FF/FF (ref ) 1 1
 158FV/FFV/FVV P = 0.456 0.87 (0.49–1.56) P = 0.647 ns P = 0.821 1.14 (0.49–2.66) P = 0.764 ns
 158V/VV P = 0.145 0.28 (0.08–1.00) P = 0.051 ns P = 0.899 0.28 (0.03–2.27) P = 0.232 ns
Allele carriage
 ≥1 158F allele P = 0.272 3.34 (0.96–11.57) P = 0.058 ns P = 0.819 3.89 (0.50–30.31) P = 0.194 ns
 ≥1 158V allele P = 0.198 0.75 (0.43–1.31) P = 0.311 ns P = 0.964 0.95 (0.42–2.19) P = 0.910 ns
FcγRIIIb
Genotype
 HNA1a+/1b−/1c− P = 0.040 0.37 (0.15–0.92) P = 0.033 ns P = 0.035 0.20 (0.04–0.96) P = 0.044 ns
 HNA1a−/1b+/1c− P = 0.565 0.69 (0.25–1.86) P = 0.459 ns P = 0.160 0.20 (0.03–1.69) P = 0.139 ns
 HNA1a−/1b−/1c+ P = 0.672 0.70 (0.18–2.78) P = 0.616 ns – – P = 0.970
 HNA1a+/1b+/1c− (ref ) 1 1
 HNA1a+/1b−/1c+ P = 0.643 0.73 (0.31–1.72) P = 0.478 ns P = 0.863 0.97 (0.33–2.79) P = 0.949 ns
 HNA1a−/1b+/1c+ P = 0.260 1.57 (0.64–3.88) P = 0.326 ns P = 0.272 1.80 (0.57–5.71) P = 0.316 ns
 HNA1a+/1b+/1c+ P = 0.086 2.36 (0.63–8.75) P = 0.201 ns P = 0.843 – ns P = 0.123
Allele carriage
 ≥1 HNA1a allotype P = 0.408 0.79 (0.43–1.46) P = 0.452 ns P = 0.986 1.01 (0.40–2.56) P = 0.981 ns
 ≥1 HNA1b allotype P = 0.020 2.02 (1.12–3.64) P = 0.019 ns P = 0.079 1.91 (0.81–4.53) P = 0.140 ns
 ≥1 HNA1c allotype P = 0.075 1.52 (0.86–2.69) P = 0.146 ns P = 0.110 1.74 (0.77–3.96) P = 0.185 ns
In utero infected In utero-enriched infected
Univariate Adjusted for VL + bwt PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
FcγRIIa (rs1801274)
Genotype
 131HH (ref ) 1 1
 131HR P = 0.456 0.71 (0.15–3.25) P = 0.657 ns P = 0.455 0.75 (0.32–1.79) P = 0.520 ns
 131RR P = 0.541 1.87 (0.45–7.79) P = 0.390 ns P = 0.433 0.77 (0.30–1.96) P = 0.581 ns
Page 12 of 16Lassaunière et al. Retrovirology  (2016) 13:40 
glycosylation and tertiary structure of the receptor [9, 
24–26]. Neutrophils from FcγRIIIb-HNA1a homozygous 
donors have an enhanced phagocytic and respiratory 
burst capacity compared to neutrophils from FcγRIIIb-
HNA1b homozygous donors [27, 28]. In the present 
study, homozygosity for the FcγRIIIb-HNA1a allotype 
in the infant was associated with reduced odds of HIV-1 
acquisition compared to other allotype combinations. In 
both mother and infant, carriage of at least one FcγRIIIb-
HNA1b allotype was associated with increased odds 
of HIV-1 acquisition. Since expression of FcγRIIIb is 
largely restricted to neutrophils, these findings suggest 
a potential role for neutrophil-mediated FcγR effector 
functions in modulating perinatal HIV-1 transmission 
and acquisition. The underlying mechanism may also 
involve basophils as FcγRIIIb is detected at low levels on 
Table 5 continued
In utero infected In utero-enriched infected
Univariate Adjusted for VL + bwt PBonf Univariate Adjusted for VL PBonf
AOR (95 % CI) P value AOR (95 % CI) P value
Allele carriage
 ≥1 131H allele P = 0.139 0.42 (0.15–1.21) P = 0.108 ns P = 0.685 1.07 (0.51–2.22) P = 0.858 ns
 ≥1 131R allele P = 0.912 1.17 (0.31–4.58) P = 0.817 ns P = 0.396 0.76 (0.34–1.70) P = 0.503 ns
FcγRIIb (rs1050501)
Genotype
 232II (ref ) 1 1
 232IT P = 0.862 0.80 (0.23–2.74) P = 0.724 ns P = 0.577 1.18 (0.56–2.50) P = 0.658 ns
 232TT P = 0.038 3.53 (0.95–13.14) P = 0.060 ns P = 0.092 2.02 (079–5.16) P = 0.144 ns
Allele carriage
 ≥1 232I allele P = 0.026 0.26 (0.08–0.86) P = 0.028 ns P = 0.110 0.54 (0.23–1.28) P = 0.160 ns
 ≥1 232T allele P = 0.298 1.33 (0.47–3.77) P = 0.593 ns P = 0.264 1.38 (0.70–2.74) P = 0.353 ns
FcγRIIIa (rs396991)
Genotype
 158F/FF/FF (ref ) 1 1
 158FV/FFV/FVV P = 0.391 0.61 (0.20–1.86) P = 0.385 ns P = 0.410 0.74 (0.37–1.49) P = 0.405 ns
 158V/VV P = 0.550 0.85 (0.16–4.42) P = 0.842 ns P = 0.073 0.29 (0.06–1.36) P = 0.117 ns
Allele carriage
 ≥1 158F allele P = 0.354 0.93 (0.19–4.53) P = 0.931 ns P = 0.190 2.91 (0.66–12.92) P = 0.160 ns
 ≥1 158V allele P = 0.740 0.66 (0.23–1.85) P = 0.425 ns P = 0.100 0.65 (0.33–1.28) P = 0.215 ns
FcγRIIIb
Genotype
 HNA1a+/1b−/1c− P = 0.709 0.77 (0.15–3.86) P = 0.748 ns P = 0.350 0.53 (0.18–1.52) P = 0.234 ns
 HNA1a−/1b+/1c− P = 0.631 0.46 (0.04–4.76) P = 0.513 ns P = 0.678 1.13 (0.37–3.42) P = 0.827 ns




 HNA1a+/1b−/1c+ P = 0.808 0.65 (0.10–4.10) P = 0.645 ns P = 0.365 0.50 (0.15–1.67) P = 0.259 ns
 HNA1a−/1b+/1c+ P = 0.077 4.47 (0.84–23.80) P = 0.080 ns P = 0.518 1.50 (0.46–4.92) P = 0.501 ns
 HNA1a+/1b+/1c+ P = 0.123 3.35 (0.40–27.73) P = 0.262 ns P = 0.017 4.44 (1.14–17.40) P = 0.032 ns
Allele carriage
 ≥1 HNA1a allotype P = 0.307 0.58 (0.19–1.76) P = 0.337 ns P = 0.258 0.66 (0.32–1.37) P = 0.265 ns
 ≥1 HNA1b allotype P = 0.231 1.82 (0.63–5.32) P = 0.271 ns P = 0.079 2.16 (1.05–4.44) P = 0.037 ns
 ≥1 HNA1c allotype P = 0.101 2.16 (0.76–6.14) P = 0.149 ns P = 0.243 1.42 (0.71–2.81) P = 0.321 ns
P values less than 0.05 are indicated in italics
PBonf Bonferroni corrected P value, AOR adjusted odds ratio, CI confidence interval, VL viral load, bwt birth weight, –, the variable of interest was not detected in any of 
the cases and thus could not be analysed
a The multivariate analysis adjusted for demographic and clinical variables that independently associated with transmission. Due to high correlation with viral load, 
CD4 T cell counts were not included in the multivariate model
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a subset of this cell population, although its function here 
is unknown.
To date, only the FcγRIIa-H131R variant has been 
studied in perinatal HIV-1 transmission, with an asso-
ciation reported between the FcγRIIa-131HH genotype 
and increased infant susceptibility [29]. This association 
was however not observed in the present study. The con-
trasting findings are likely attributable to study design. 
In the Brouwer et al. study, infants were considered peri-
natally infected if PCR positive at or before 4  months 
of age where in the present study infant infection status 
was determined up to 6  weeks of age. The implication 
thereof is that the number of infants that acquired HIV-1 
through breastfeeding is likely higher in the Brouwer 
et al. study compared to the 12.8 % in the present study. 
If this is the case, the findings of the Brouwer et al. study 
may be more representative of an association with HIV-1 
transmission through breastfeeding, rather than in utero 
or intrapartum transmission.
Perinatal HIV-1 transmission is an attractive model 
in which to study the role of antibodies and their effec-
tor functions in HIV-1 protective immunity. This rep-
resents a natural situation where the individual at risk 
is passively immunized with HIV-1-specific antibod-
ies through transplacental transfer of IgG [30, 31]. This 
model also affords the opportunity to study both mem-
bers of the transmitting dyad, allowing the assessment 
of factors contributing to the infectiousness of the trans-
mitter (mother) as well as the susceptibility of the recipi-
ent (infant). The findings of this study therefore not only 
highlight additional immunological factors associated 
with risk of perinatal HIV-1 transmission, but further 
support a role for FcγR-mediated effector functions 
in HIV-1 protective immunity. In particular, findings 
underscore a potential involvement of neutrophils in 
protection from HIV-1 transmission and a possible role 
of FcγR-mediated effector functions in modulating the 
infectiousness of an HIV-1 infected individual. The sig-
nificance of these findings in the context of sexual trans-
mission will need to be determined.
There are a number of limitations of the current study 
and areas that require further investigation. Due to the 
small sample size and number of comparisons performed 
it is likely that a number of associations are due to chance. 
However, since the adjustment for multiple comparisons 
eliminate type I errors at the cost of type 2 errors, we 
considered it more important to identify potential fac-
tors that may play a role in perinatal HIV-1 transmission 
rather than dismissing these leads as chance variations 
brought about by multiple comparisons. Nonetheless, 
when a Bonferroni correction is applied (α  =  0.0012), 
the association with the maternal FcγRIIIa-F158V vari-
ant in the in utero-enriched transmitting group remains 
significant.
Conclusions
The maternal and infant immune mechanisms involved 
in modulating the risk of perinatal HIV-1 transmission 
and acquisition are complex and multifactorial. Using the 
approach of studying FcγR genetic variants as proxy for 
functional capability, this study has revealed the poten-
tial importance of FcγR-mediated immune mechanisms 
that likely involve FcγRIIIa-bearing immune cells and 
neutrophils. The findings of this study need to be vali-
dated in larger cohorts, in particular associations that did 
not retain significance following adjustment for multiple 
comparisons. Moreover, understanding the role of IgG 
Fc-mediated mechanisms requires an appreciation for 
Fig. 2 LD for FcγR variants in the study cohort comprising Black South African HIV-1 infected mothers (left) and their infants (right). Values and 
colours reflect r2 (× 100) and D′/LOD measures of LD, respectively. The black triangle depicts a haplotype block that is indicative of the relationship 
between the FcγRIIIb-HNA1b and -HNA1c allotypes. Such that HNA1b and HNA1c are identical at amino acid position 65 (p.65S) and differ only at 
amino acid position 78 (p.78A1b>D1c)
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the collective contribution of multiple components in 
addition to FcγR genetic variants. These include factors 
such as the magnitude and specificity of maternal HIV-1 
specific antibodies, the efficiency of antibody transfer 
Table 6 Multivariate analysis adjusted FcγRIIIa-F158V
P values less than 0.05 are indicated in italics
PBonf Bonferroni corrected P value, AOR adjusted odds ratio, CI confidence interval, VL viral load, bwt birth weight, ns not statistically significant




PBonf Multivariate analysis with adjustment for FcγRIIIa-F158V genotype and allele carriage




 Total transmitting P = 0.023 ns 1.93 (0.82–4.57), 
P = 0.133
ns 2.25 (0.97–5.24), 
P = 0.133
ns 2.08 (0.89–4.86), 
P = 0.091
ns
 In utero transmitting P = 0.029 ns 9.37 (1.01–87.22), 
P = 0.049
ns 9.59 (1.05–87.37), 
P = 0.045
ns 10.26 (1.12–94.28), 
P = 0.040
ns
 In utero-enriched 
transmitting
P = 0.048 ns 1.94 (0.66–5.70), 
P = 0.226
ns 2.60 (0.90–7.52), 
P = 0.077




 In utero transmitting P = 0.045 ns 0.42 (0.14–1.29), 
P = 0.132
ns 0.40 (0.14–1.15), 
P = 0.088




 Total transmitting P = 0.049 ns 1.80 (0.84–3.85), 
P = 0.128
ns 1.90 (0.89–4.05), 
P = 0.095





 Total transmitting P = 0.030 ns 2.06 (0.78–5.41), 
P = 0.144
ns 2.48 (0.96–9.36), 
P = 0.060




 Total transmitting P = 0.043 ns 0.49 (0.20–1.20), 
P = 0.118
ns 0.43 (0.18–1.05), 
P = 0.063





 Total transmitting P = 0.014 ns 2.26 (1.22–4.17), 
P = 0.009
ns 2.19 (1.20–4.02), 
P = 0.011
ns 2.21 (1.20–4.11), 
P = 0.011
ns
 In utero-enriched 
transmitting
P = 0.031 ns 2.43 (1.15–5.16), 
P = 0.020
ns 2.32 (1.11–4.82), 
P = 0.025







 Total infected P = 0.033 ns 0.37 (0.15–0.93), 
P = 0.034
ns 0.37 (0.15–0.91), 
P = 0.031
ns 0.37 (0.15–0.93), 
P = 0.034
ns
 Intrapartum infected P = 0.044 ns 0.20 (0.04–0.96), 
P = 0.044
ns 0.19 (0.04–0.95), 
P = 0.043





 In utero-enriched 
infected
P = 0.032 ns 5.67 (1.39–23.11), 
P = 0.016
ns 4.47 (1.13–17.64), 
P = 0.032




 Total infected P = 0.019 ns 2.11 (1.16–3.83), 
P = 0.014
ns 2.04 (1.12–3.69), 
P = 0.019
ns 2.08 (1.15–3.77), 
P = 0.016
ns
 In utero-enriched 
infected
P = 0.037 ns 2.29 (1.10–4.76), 
P = 0.026
ns 2.22 (1.07–4.58), 
P = 0.032
ns 2.26 (1.09–4.68), 
P = 0.028
ns
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across the placenta, immune cell phenotypes at the sites 
of HIV-1 exposure, and the impact of the overall immune 




All study participants were Black South African individu-
als. Ethical clearance was obtained from the University 
of the Witwatersrand Human Research Ethics Commit-
tee and the Institutional Review Board of Columbia Uni-
versity. Written informed consent was obtained from all 
participants.
Cohort HIV-1 infection status
Maternal HIV-1 RNA levels were determined using the 
Roche Amplicor RNA Monitor assay version 1.5 (Roche 
Diagnostic Systems, Inc., Branchburg, New Jersey, USA). 
CD4+ T cell counts were determined using the FACS-
Count System from Becton–Dickinson (San Jose, CA, 
USA). Infant samples were tested for HIV-1 DNA using 
the Roche Amplicor Monitor version 1.5 qualitative PCR 
assay (Roche Diagnostic Systems).
FCGR gene copy number variability and nucleotide variant 
detection
Genomic DNA was extracted from EDTA anticoagu-
lated blood samples using the QIAamp DNA Mini Kit 
(Qiagen, Dusseldorf, Germany). Functional FCGR vari-
ants were genotyped using the FCGR-specific multiplex 
ligation-dependent probe amplification (MLPA) assay 
(MRC Holland, Amsterdam, The Netherlands) according 
to manufacturer’s instructions [19, 20]. The assay detects 
the genomic copy number of the FCGR2C, FCGR3A and 
FCGR3B genes and known functional allelic variants that 
include FcγRIIa-H131R; FcγRIIb-I232T, FcγRIIIa-F158V, 
FcγRIIIb-HNA1a|b|c, FCGR2C expression variants 
(p.X57Q and c.798+1A>G), and the FCGR2B/C pro-
moter variants (c.-386G>C and c.-120T>A). Genotypes 
assigned to study participants according to the MLPA 
assay were confirmed on randomly selected samples 
with nucleotide sequencing or TaqMan® SNP Genotyp-
ing Assays (Thermofisher, Life Technologies, Foster City, 
USA).
Computational and statistical analysis
Univariate analyses were used to determine the asso-
ciation between FcγR functional variants and perinatal 
HIV-1 transmission. Multivariate logistic regression was 
used to adjust for available confounders that were inde-
pendently significantly associated with HIV-1 transmis-
sion i.e. viral load (all groups) and birth weight (in utero 
transmitting group) (Table  1). Due to high correlation 
with viral load, CD4 T+ cell count was not included in 
the multivariate model. The t test was used to compare 
normally distributed continuous variables and the Fish-
er’s exact test for categorical data. All analyses were per-
formed in STATA version 10.1 (StataCorp LP, College 
Station, USA) and a P value of less than 0.05 was con-
sidered statistically significant. Adjustment for multiple 
comparisons was performed using the Bonferroni cor-
rection, which considered 42 independent tests—moth-
ers and infants, three unrelated clinical subgroups, and 
seven loci (FCGR3A gene copy number, FCGR3B gene 
copy number, FcγRIIa-H131R, FcγRIIb-I232T, FcγRIIIa-
F158V, FcγRIIIb-HNA1a|b|c, and overall FcγR variability 
profiles).
LD between pairs of biallelic loci was tested using an 
expectation–maximization likelihood-ratio test with 16 
000 permutations (significance level <0.05) in Arlequin 
ver 3.5.2.2 [32]. LD coefficients (D′ and r2) were deter-
mined in Haploview [33]. Only individuals bearing two 
copies of each low affinity FCGR gene were considered. 
LD with FcγRIIIb-HNA1a|b|c was assessed using two 
loci: rs448740 (p.N65S; as tag-variant) that differentiates 
HNA1a (p.65  N) from HNA1b|c (p.65S) and rs5030738 
(p.A78D) that differentiates HNA1a|b (p.78A) from 
HNA1c (p.78D).
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